Article Text

Download PDFPDF

Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’
  1. Cloé Comarmond1,2,
  2. Mathilde Leclercq1,
  3. Gaëlle Leroux1,
  4. Cindy Marques1,3,
  5. Alexandre Le Joncour1,3,
  6. Fanny Domont1,
  7. Céline Hatte1,
  8. Ségolène Toquet-Bouedec1,2,
  9. Perrine Guillaume-Jugnot1,
  10. Anne-Claire Desbois1,2,
  11. Mathieu Vautier1,
  12. Aude Rigolet1,
  13. Yves Allenbach1,2,3,
  14. Olivier Benveniste1,2,3,
  15. David Saadoun1,2,3,
  16. Patrice Cacoub1,2,3
  1. 1 Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France
  2. 2 Sorbonne Université, Paris, France
  3. 3 DHU Inflammation, Immunopathologie, Biothérapie, Paris, France
  1. Correspondence to Dr Cloé Comarmond, Internal Medicine and Clinical Immunology, Pitié-Salpêtrière Hospital, 83 bd de l'Hôpital 75013 Paris, Assistance Publique - Hôpitaux de Paris, Paris, Île-de-France, France; clocomarmond{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

COVID-19, caused by the SARS-CoV-2, is an unprecedented global pandemic. Advanced age and cardiovascular diseases are recognised as major comorbidities associated with severe forms of COVID-19. Patients with large vessels vasculitis (LVV) could be considered at-risk for severe COVID-19 due to frequent age over 65 years in patients with giant cell arteritis (GCA), severe hypertension in patients with Takayasu arteritis (TAK) and current use of immunomodulating therapies in both LVV. Data on prevalence, clinical presentation and outcome of SARS-CoV-2 infection among patients with LVV are lacking.1–3 Tomelleri et al reported their experience in a single tertiary centre in Lombardy, the Italian region with the highest proportion of infected subjects.2 Their incidence rate of confirmed COVID-19 infection by nasopharyngeal PCR was 2.5% (4/162). Two patients required hospitalisation for COVID-19 interstitial pneumonia and no death was observed. We report our experience on clinical presentation and outcome of COVID-19 among patients with LVV in Paris-Ile de France, another region particularly affected during the same period.

A phone survey was conducted between 04 and 20 May 2020, 8 weeks after lockdown started in France, among patients with LVV followed in Pitié-Salpêtrière Hospital (Paris, France). Patients with positive nasopharyngeal PCR and/or thoracic CT scan suggestive of COVID-19 and/or serological tests detecting anti-SARS-CoV-2 antibodies were considered as confirmed diagnosis of COVID-19. We retrospectively collected severity of COVID-19 infection, therapeutic management and outcomes.

A total of 148 patients with LVV (84 GCA and 64 TAK) were included. Among them, eight patients (four GCA and four TAK) had a confirmed SARS-CoV-2 infection: two had both RT-PCR positive and suggestive thoracic CT scan, one had RT-PCR positive, one had suggestive thoracic CT scan and four had positive serology. Main data are summarised in table 1. The incidence rate was 5.4%. Interestingly, seven patients had quiescence LVV at the time of COVID-19 infection, seven patients were currently treated with prednisone and two with tocilizumab. Six patients have been in close contact with COVID-19-infected people. The most common symptom was fatigue (88%), followed by fever (75%) and dyspnoea (63%). Pneumonia occurred in three patients, all requiring hospitalisation with oxygen therapy for two patients. Most of the patients (75%) did not need LVV treatment changes or discontinuation. Only one patient with TAK needs mechanical ventilation and died few days after his admission in intensive care unit. The lethality rate was 12.5% (1/8). Interestingly, among patients with LVV, we observed two other deaths during same period, considered as COVID-19-related deaths (both with acute respiratory distress syndrome) but no confirmation of infection. Mortality rate reached 2% in our patients with LVV (3/148).

Table 1

Baseline characteristics and treatments of LVV patients with confirmed or probable COVID-19

The incidence rate of COVID-19 in our LVV cohort (5.4%) was lower compared with the risk of infection observed in the general population in the same region (12.3% in Ile-de-France including Paris). However, COVID-19 appeared to be more severe in LVV, requiring hospitalisation in up to 37.5% of COVID-19-infected LVV patients. In comparison, modelling analyses of SARS-CoV-2 transmission in France estimated the risk of hospitalisation around 21% in individuals >80 years and 9.6% in the group 70–79 years.4 We also observed a high lethality rate (12.5%) among LVV-COVID+ compared with the lethality rate of 8% reported among infected individuals >80 years and 2.2% in group 70–79 years in the French general population.4 Among 600 patients with rheumatic diseases from 40 countries, Gianfrancesco et al 5 found a rate of hospitalisation of 46%. This study included 44 patients (7%) with vasculitis and 12 polymyalgia rheumatica. Use of disease-modifying antirheumatic drug or biological therapies was not associated with an increased risk of hospitalisation.

The lethality rate of our cohort (12.5%) was higher compared with other studies (1.69%) on patients with inflammatory disease (psoriasis, inflammatory rheumatism or chronic inflammatory bowel disease, no vasculitis) receiving immunomodulator/immunosuppressive therapies.6 However, our lethality rate was closer to the international study of Gianfrancesco et al (9%).5 Tomelleri et al 2 reported a better prognosis of COVID-19 among patients with LVV with only two COVID-19-related hospitalisation and no death, including the two elderly patients with GCA requiring hospitalisation. Of note, among the 162 patients with LVV from Lombardy, 53 (33%) patients were treated with tocilizumab compared with 10% in our LVV cohort. Tocilizumab may have had a positive impact on COVID-19 outcome in the Italian cohort and appears as a potential therapeutic option.7 Glucocorticoids (such as dexamethasone at a dose of 6 mg once per day during 10 days) could also modulate inflammation-mediated lung injury caused by Sars-Cov-2 and may reduce 28-day mortality among pneumonia requiring invasive mechanical ventilation or oxygen.8 Future studies will need to clarify the impact of tocilizumab and glucocorticoids on COVID-19 outcome in patients with LVV.

Despite limited number of LVV-COVID+ hospitalised in our cohort, this data suggests that COVID-19 seems to be more severe in patients with LVV with higher rates of hospitalisation and lethality.

Ethics statements

Patient consent for publication



  • CC and ML are co-first authors.

  • Contributors CC, ML and PC designed the study. All authors collected the data. CC, ML and ALJ conducted the statistical analysis. CC, ML and PC wrote the manuscript. All authors critically reviewed and approved the final version of the manuscript. CC, ML and PC took full responsibility for the integrity of the work. CC and ML contributed equally to this work and are co-first authors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles